NewAmsterdam Pharma (NAMS) Capital Expenditures (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted Capital Expenditures of $38000.0 for Q1 2026, down 62.0% sequentially from $100000.0 in Q4 2025, and up 137.5% YoY from $16000.0 in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Capital Expenditures (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Capital Expenditures for 4 years, with the latest figure at $38000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 137.5% year-over-year to $38000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268000.0 (down 11.55% YoY) and the FY2025 annual result came in at $246000.0, down 63.39% from the prior year.
- Capital Expenditures fell to $38000.0 in Q1 2026 per NAMS's latest filing, from $100000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $385000.0 in Q1 2024 and troughed at $3000.0 in Q4 2023.
- A 4-year average of $75384.6 and a median of $38000.0 in 2026 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures jumped 5400.0% in 2024, then slumped 95.84% in 2025.
- Over 4 years, Capital Expenditures stood at $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then soared by 3233.33% to $100000.0 in 2025, then plunged by 62.0% to $38000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $38000.0, $100000.0, and $42000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | 80,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 80,000.00 |
| Mar 31, 2026 | 38,000.00 |
| Dec 31, 2025 | 100,000.00 |
| Sep 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 75,000.00 |
| Jun 30, 2024 | 209,000.00 |
| Mar 31, 2024 | 385,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 9,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | 7,000.00 |